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More than 10% of all men will be given the diagnosis “prostate cancer” during their 
lifetime. Most of the current radio-diagnostic vehicles involve both expensive and 
localized production with cyclotrons as well as the use of bulky chelators for the 
radiometal. We report the use of a new multifunctional cyclopentadiene (Cp) platform to 
prepare difunctional and monofunctional, PSMA-targeting rhenium and technetium-99m 
complexes. The Cp-complexes and the free ligands are prepared by straightforward 
functionalization with either one or two Lys-urea-Glu (LuG) PSMA binding motifs. Cell 
binding assays revealed that the difunctional rhenium complex displays a dissociation 
constant (KD = 2.1 nM) that is an order of magnitude lower than the monofunctional 
compound (KD = 24.2 nM). The 99mTc complexes can be prepared in one step and ≤ 15 
min in high yields. These difunctional Cp-Re(I)/99mTc(I) complexes represent a new class 
of imaging agents with binding affinities comparable to clinically evaluated compounds. 
Additionally, this study demonstrates that the Cp-platform can readily be derivatized with 
amine-containing biomolecules. Extending this work to incorporate both targeting and 
therapeutic moieties could lead to theranostic systems with Re/99mTc. 
 
In the 21st century, one out of nine men will be diagnosed with prostate cancer during his 
lifetime. While current treatments have vastly increased the mean survival rate of patients, 
over 30’000 people are still expected to die from prostate cancer in 2019 in the US 
alone.[1] The most common cause of mortality in prostate cancer patients is the 
occurrence of metastases. A major factor in reducing the death toll of this disease is the 
improvement of early detection and monitoring techniques. The prostate specific 
membrane antigen (PSMA) is an extracellular receptor and a promising target for nuclear 
imaging as its overexpression is proportional to the stage and grade of tumor 
progression.[2] Many PSMA-binding imaging agents based on 11C, 18F, 64Cu, 68Ga, 86Y, 
89Zr, 99mTc, 111In, and various radionuclides of iodine have been reported.[3] The necessity 
and associated high cost of a cyclotron for the generation of most of these radionuclides 
limits their widespread availability. 68Ga and 99mTc are exempt from this limitation as these 
two radionuclides can be delivered over large distances by means of relatively low-cost 
generators. New imaging agents based on both gallium and technetium chelators coupled 
to a high PSMA-affinity Lys-urea-Glu (LuG) motif are currently in advanced clinical trials.[4] 
Multifunctional radiotracers containing more than one binding unit have higher binding 
avidity to membrane-proteins. This has already been exploited with integrin αvβ3 protein-
targeted radiotracers linked to cyclic arginine-glycine-aspartic (RGD) peptides.[5] Multiple 
studies found superior binding for difunctional RGD-chelates compared to their 
monofunctional counterparts.[6] Indeed, 99mTc-3PRGD2 is a difunctional cyclic RGD-
based imaging agent which is currently undergoing multiple phase I clinical trials.[7] In light 
of these promising results, it is surprising that little work has been done on multifunctional 
PSMA-targeting compounds. In 2012, Schäfer et al. reported a 68Ga-based structure 
containing two LuG units that displayed improved PSMA affinity, higher cell uptake and 
prolonged cell surface retention time compared to the monofunctional analogue.[8] To the 
best of our knowledge, the only 99mTc-complexes conjugated to multiple PSMA-binding 
units were reported by Frangioni and coworkers in 2007. They prepared difunctional and 
trifunctional 99mTc(V) compounds based on a phosphinyl-containing PSMA-ligand. The 
bi- and trifunctional complexes showed significantly higher PSMA affinities than their 
monofunctional counterpart.[9] These promising preliminary results illustrate that there is 
unexplored potential in multifunctional PSMA-targeted radiotracers. 
In this work, we describe the synthesis and evaluation of a compact Re/99mTc(I) system 
containing either one or two LuG units. In other reported PSMA-binding systems, the 
chelator is often as large or even larger as the LuG moiety. Cyclopentadiene (Cp) ligands 
are ideal chelators for the Re/99mTc(I) tricarbonyl system due to their small size, high 
stability of the formed complexes, and the possibility to functionalize them with one or 
more targeting units.[10] By using a multifunctional Cp as both the metal-coordinating 
moiety and as the linker to the two PSMA-ligands the usually large and bulky chelating 

























Scheme 1. Synthesis of LuG. Reaction conditions: i) triphosgene, triethylamine (NEt3), dry 
CH2Cl2, 0 – 25 °C, 6 h, 65%. ii) H2, Pd/C (10%), MeOH, 25 °C, 16 h, 96%.  
In recent work, our group has prepared Cp-ligand 1 through a straightforward synthesis 
adapted from Hatanaka et al. and found that the respective Cp-piano stool type 
complexes of [Re(CO)3]+ and [99mTc(CO)3]+ could be prepared readily and in good yields. 
The two ester-groups of 1 are sufficiently different in reactivity on the free Cp to allow for 
step-wise hydrolysis and functionalization with amine-bearing functionalities.[11] The 
rhenium complexes Re1 and Re2 were prepared from compound 1 based on a synthetic 
strategy recently reported by our group. LuG was prepared according to a previously 
reported procedure and reacted with 2 and 3 using hydroxybenzotriazole (HOBt) and 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (Scheme 1 and 2).[12] The resulting 
complexes (2b and 3b, see Supporting Information) were purified by preparative HPLC. 
In the case of 3b, the two diastereomers resulting from combining the planar chirality of 
the rhenium complex with the enantiomerically pure LuG could be separated and 
characterized (3b’ and 3b’’, Figure S9). In the case of 2b, the diastereomers could not 
be separated but the 13C NMR revealed two sets of peaks for all carbons, indicating their 
presence in a 1:1 ratio (Table S1). The tert-butyl protecting groups were cleaved with 
NaOH in MeOH under microwave (MW) conditions and further purification by preparative 
HPLC yielded pure Re1 and Re2. Upon hydrolysis of 3b’ and 3b’’, the resulting 
compounds could not be differentiated anymore by either HPLC or NMR experiments 
(Figure S26 and S27). Hence, in a new batch, the diastereomers of 3b were not separated 
and used as a mixture for the deprotection step. This yielded the final compound Re2 as 
a mixture of diastereomers. The complexes were characterized by NMR spectroscopy 




























































































































Scheme 2. Synthetic route to Re1 and Re2. Reaction conditions: i) 0.5 eq NaOH, MeOH, MW, 
120 °C, 15 min. ii) Re2CO10, N,N-dimethylformamide (DMF), MW, 220 °C, 15 min. iii) LuG, HOBt, 
EDC, N,N-diisopropylethylamine (DIPEA), DMF, 25 °C, 24 h, 30% (from 1). iv) NaOH, MeOH, 
MW, 120 °C, 15 min, 76%. v) Re2CO10, o-Xylene, MW, 220 °C, 15 min, 76%. vi) NaOH, MeOH, 
MW, 120 °C, 15 min, 68%. vii) LuG, HOBt, EDC, DIPEA, DMF, 25 °C, 24 h, 31%. viii) NaOH, 
MeOH, MW, 120 °C, 15 min, 56%. 
 
To determine the PSMA-binding affinity of Re1 and Re2, LNCaP (PSMA-positive) and 
PC-3 (PSMA-negative) cells were incubated for 1 h with different concentrations of the 
rhenium complexes.[13] The cells were then washed, digested, and the total amount of Re 
was determined by inductively coupled plasma mass spectrometry (ICP-MS). Both 
compounds displayed binding affinities in the low nanomolar range for the LNCaP cells 
(Figure 1). With a KD of 2.1 nM, the binding affinity of the difunctional complex Re2 was 
12 times higher than for the monofunctional Re1 (24.2 nM) and on par with PSMA-binders 
currently in clinical trials.[14] In the PC-3 negative controls, no significant binding (< 0.05 
ppb Re) was observed for both complexes at all tested concentrations. The tenfold higher 
non-specific binding (NS) observed for Re1 as compared to Re2 could stem from the 
difference in hydrophilicity of the two compounds. Re2 comprises six carboxylate groups 
compared to only four on Re1. The difference in hydrophilicity is also evident from their 
different UPLC retention times (Re1: 2.35 min vs. Re2: 2.16 min).  From the calculated 
Bmax value and the known number of cells per sample an estimate of around 106 binding 
sites per LNCaP cell was obtained which is in good agreement with literature reports and 
supports the values obtained in our experiments.[15]  Interestingly, the amount of rhenium 
detected at the highest incubation concentrations (Bmax) for Re1 was almost twice that of 
Re2. A possible explanation for this finding is that Re2 is able to occupy two PSMA 
binding sites per rhenium atom, resulting in a lower amount of overall rhenium, while for 
Re1, only one rhenium atom is expected per one binding site.  
Figure 1. PSMA-binding affinity of complexes Re1 and Re2. Binding affinities were obtained by 
fitting rhenium content of cell-samples incubated with different concentrations of complex. Each 
data point is the average of three different samples (error bars indicate standard deviation). 
 
Having confirmed the ability of Re1 and Re2 to bind PSMA efficiently, the next step was 
to demonstrate that the corresponding 99mTc complexes can be prepared under 
radiolabeling conditions. Therefore, the free ligands 4 and 5 were prepared from 1 and  
LuG in two steps (Scheme 3). The pure ligands were then applied directly and without 
deprotection for radiolabeling with 99mTc. Reacting 4 and 5 (5 mM) with 
[99mTc(OH2)3(CO)3]+ at 140 °C in a microwave reactor in water at pH = 13 (adjusted with 
1 M NaOH) led to formation of Tc1 and Tc2 presumably as diastereomeric mixtures (as 
with rhenium) within 15 min, as evidenced by HPLC co-injection with the respective 
rhenium complex (Figure 2, non-optimized radiochemical yields of crude reaction: 61% 
and 74% respectively). The main side-products were [99mTcO4]- and [99mTc(OH2)3(CO)3]+. 
The peak for Tc2 was observed to be rather broad, which can partly be ascribed to the 
fact that the gamma detector will register radioactivity a little while before and after the 
compound enters the detector area. The shoulders of the peak could indicate that some 
tert-butyl protecting groups are still present in the crude, leading to peaks with slightly 
































































































Scheme 3. Synthetic route to Tc1 and Tc2. Reaction conditions: i) a) 0.93 eq. NaOH, MeOH, 
MW, 120 °C, 15 min. b) LuG, HOBt, EDC, DIPEA, DMF; 25 °C, 24 h, 17% (from 1). ii) a) NaOH, 
MeOH, MW, 120 °C, 15 min. b) LuG, HOBt, EDC, DIPEA, DMF; 25 °C, 24 h, 15% (from 1). iii) 
[99mTc(OH2)3(CO)3]+, H2O (pH = 13), MW, 140 °C, 15 min. iv) [99mTc(OH2)3(CO)3]+, H2O (pH = 
13), MW, 140 °C, 10 min. 
Figure 2. UV (254 nm) and γ-traces of the co-injection of the rhenium compounds Re1 and Re2 
with the 99mTc compounds Tc1 and Tc2 respectively. Time differences are due to detector 
separation. 
 
This work demonstrates that our previously developed cyclopentadiene-system lends 
itself to easy and straightforward functionalization with biomolecules. The coupling 
reactions proceed with good overall yields and the products are readily purified by 
preparative HPLC.  Importantly, the synthesis of the respective 99mTc complexes is also 
possible from highly pre-functionalized Cp-ligands, in one step and in 15 min or less. The 
successful conjugation of two targeting units to our platform opens up the possibility to 
attach both a targeting and a cytotoxic moiety to the complex, which could lead to targeted 
chemotherapeutic compounds. In conclusion, this proof-of-concept illustrates the 
potential of multifunctional Cp-ligands in radiotracer design, and encourages their 
application with further targeting and bioactive modalities. 
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Materials.  All chemicals were of reagent-grade quality or higher and were obtained from 
commercial suppliers. Solvents were used as received or dried over molecular sieves. 
Sodium boranocarbonate was a gift from Mallinckrodt Medical B.V. (The Netherlands). 
Na[99mTcO4] in 0.9% saline was eluted from a 99Mo/99mTc UTK FM generator purchased 
from Mallinckrodt Medical B.V. (The Netherlands) 
 
Instrumentation and methods. 1H and 13C NMR spectra were recorded in deuterated 
solvents on a Bruker DRX 400 (1H: 400 MHz, 13C: 100.6 MHz) or DRX 500 (1H: 500 MHz 
13C: 125.8 MHz) MHz spectrometer at 300 K. The chemical shifts, 𝛿𝛿, are reported in ppm 
(parts per million) relative to residual solvent peaks. The abbreviations for the peak 
multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q 
(quartet), m (multiplet), br (broad). Microwave reactions were performed using a Biotage 
Initiator+ Robot Eight or Anton Paar (AP) Monowave 200 instrument. UPLC-ESI-MS was 
performed on a Waters Acquity UPLC System coupled to a Bruker HCTTM, using an 
Acquity UPLC BEH C18 1.7μm (2.1 x 50 mm) column. UPLC solvents were formic acid 
(0.1% in millipore water) (solvent A) and acetonitrile UPLC grade (solvent B). The 
temperature was regulated with a Peltier thermostatic system to the specified 
temperatures. High-resolution mass spectrometry (HR-MS) was performed on a Thermo 
DFS double-focusing system (ThermoFisher Scientific, Germany). Preparative HPLC 
was performed on a Varian ProStar 320 system, using a Dr. Maisch Reprosil C18 100-7 
(40 x 250 mm) column (flow rate: 40.0 ml/min) or a LiChroCART RP-18e (10 x 250 mm) 
column. HPLC solvents were 0.1% trifluoroacetic acid (solvent A) and acetonitrile (solvent 
B), HPLC grade. Analytical HPLC was performed on a Merck Hitachi L7000 system, 
equipped with a L-7400 UV-detector and an in-line radio-detector Berthold FlowStar 
LB513, using an analytical Macherey-Nagel Nucleosil C18 5 μm (4.6 × 250 mm) column. 
Analytical UPLC was performed on a VWR Hitachi Chrommaster Ultra, using an Acquity 
UPLC BEH C18 1.7 μm (2.1 x 50 mm) column. UPLC solvents were trifluoroacetic acid 




UPLC-MS. The UPLC-MS runs (flow rate 0.6 mL/min) were performed with a linear 
gradient of A (acetonitrile (Sigma-Aldrich HPLC-grade)) and B (distilled water containing 
0.1 % formic acid): t = 0–0.5 min, 5 % A; t = 4.0 min, 100 % A; t = 5.0 min, 100% A. 
UPLC (U1). The UPLC runs (flow rate 0.5 mL/min) were performed with a linear gradient 
of A (acetonitrile (Sigma-Aldrich HPLC-grade)) and B (distilled water containing 0.1% 
TFA): t = 0–0.5 min, 5% A; t = 4.0 min, 100% A; t = 5.0 min, 100% A. 
HPLC. The HPLC runs (flow rate 0.5 mL/min) were performed with a linear gradient of A 
(acetonitrile (Sigma-Aldrich HPLC-grade)) and B (distilled water containing 0.1 % TFA): t 
= 0–2.1 min, 10% A; t = 25 min, 100% A; t = 35 min, 100% A; t = 37 min, 10% A; t = 40 
min, 10% A. 
radioHPLC. The radioHPLC runs (flow rate 0.5 mL/min) using a gradient of A (MeOH (Sigma-
Aldrich HPLC-grade)) and B (distilled water containing 0.1 % TFA t = 0 – 3 min: 10% A; 3 – 3.1 
min: 0 – 25% A; 3.1 – 9 min: 25% A; 9 – 9.1 min: 25 – 34% A; 9.1 – 18 min: 34 - 100% A; 
18 – 25 min: 100% A, 25 – 25.1 min: 100 - 10% A; 25.1 – 30 min: 10% MeOH. Comparison 
of the HPLC retention times for the 99mTc compounds with the corresponding 99Tc and Re 
compound confirms identity. 
Preparative HPLC (Method A). The preparative HPLC runs (flow rate 40 mL/min) were 
performed with a linear gradient of A (acetonitrile (Sigma-Aldrich HPLC-grade)) and B 
(distilled water containing 0.1% TFA): t = 0–2.1 min, 10% A; t = 25 min, 100% A; t = 40 
min, 100% A. 
99mTc experiments. Caution! 99mTc is a γ-emitter (E= 140 keV, t1/2= 6.02 h) which should 
only be handled by trained personnel in a licensed and appropriately shielded facility. 
Sodium boranocarbonate releases CO gas which is highly toxic, it is recommended to be 
handled only in ventilated hoods. 
Cell culture 
Cell lines were obtained from American Type Culture Collection (ATCC). LNCaP cells 
were maintained in RPMI 1640 medium without phenol red (Gibco) at 37 °C, 5% CO2. 
PC-3 cells were maintained in DMEM/F12 medium (Gibco) at 37 °C, 5% CO2. Cell culture 
media were supplemented with 10% fetal bovine serum (Gibco) and penicillin-
streptomycin (Invitrogen).  
Cell binding assay 
Cells were harvested at 70% confluence, washed once with PBS and resuspended in full 
medium. For cell binding assays, aliquots of 5 • 106 cells were incubated with the indicated 
concentrations of the complexes in 5 ml medium for 1 hour at 4 °C. Thereafter, cells were 
collected by centrifugation at 100 g and 4 °C for 10 min, and washed three times with ice-
cold PBS.  
ICP-MS sample preparation. 
Cell pellets were digested in 150 μL ultrapure HNO3 (60%) at 80 °C overnight, 
supplemented with 60 μlLNH4F (1.011 M) filtered and diluted with Millipore water to a final 
volume of 3 ml. 
ICP-MS measurements 
Rhenium was measured against a Re single element standard (Merck 170344.100) and 
verified by a control (Agilent5188-6524 PA Tuning 2). The rhenium content of the samples 
was determined by means of 6 calibration standards that were produced in the range 
between 0 and 100 ppb in Re (R2 > 0.99) with a background equivalent concentration of 
BEC: 9.4 ppt and a detection limit of DL: 2.6 ppt. The isotope 185Re (37.4% abundance) 
187Re (62.6% abundance) was evaluated in “no-gas” mode and He-gas mode. Spiking 
the samples with untreated negative controls (to account for potential carbon content from 
the biological samples) resulted in equivalent values within error ranges. A solution 
containing indium (100 ppb) was used as internal standard. The results are expressed as 
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